|
1
|
Vogel A, Risser R and Pollack R: Isolation
and characterization of revertant cell lines. 3. Isolation of
density-revertants of SV40-transformed 3T3 cells using colchicine.
J Cell Physiol. 82:181–188. 1973. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pollack RE, Green H and Todaro GJ: Growth
control in cultured cells: Selection of sublines with increased
sensitivity to contact inhibition and decreased tumor-producing
ability. Proc Natl Acad Sci USA. 60:126–133. 1968. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Verderame M, Alcorta D, Egnor M, Smith K
and Pollack R: Cytoskeletal F-actin patterns quantitated with
fluorescein isothiocyanate-phalloidin in normal and transformed
cells. Proc Natl Acad Sci USA. 77:6624–6628. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kopelovich L, Conlon S and Pollack R:
Defective organization of actin in cultured skin fibroblasts from
patients with inherited adenocarcinoma. Proc Natl Acad Sci U S A.
74:3019–3022. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shin SI, Freedman VH, Risser R and Pollack
R: Tumorigenicity of virus-transformed cells in nude mice is
correlated specifically with anchorage independent growth in vitro.
Proc Natl Acad Sci USA. 72:4435–4439. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Steinberg BM, Rifkin D, Shin S, Boone C
and Pollack R: Tumorigenicity of revertant from an SV40-transformed
line. J Supramol Struct. 11:539–546. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang Y, Marino-Enriquez A, Bennett RR, Zhu
M, Shen Y, Eilers G, Lee JC, Henze J, Fletcher BS, Gu Z, et al:
Dystrophin is a tumor suppressor in human cancers with myogenic
programs. Nat Genet. 46:601–606. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fernandez K, Serinagaoglu Y, Hammond S,
Martin LT and Martin PT: Mice lacking dystrophin or alpha
sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with
cancer-associated p53 mutations and alternatively spliced or mutant
Mdm2 transcripts. Am J Pathol. 176:416–434. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Parry ML, Ramsamooj M and Blanck G: Big
genes are big mutagen targets: A connection to cancerous, spherical
cells? Cancer Lett. 356(2 Pt B): 1–482. 2015.
|
|
10
|
Parry ML and Blanck G: Flat cells come
full sphere: Are mutant cytoskeletal-related proteins
oncoprotein-monsters or useful immunogens? Hum Vaccin Immunother.
12:120–123. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fawcett TJ, Parry ML and Blanck G: A Novel
Approach to Evaluating Cancer Driver Gene Mutation Densities:
Cytoskeleton-related Gene Candidates. Cancer Genomics Proteomics.
12:283–290. 2015.PubMed/NCBI
|
|
12
|
Zachary JM, Cleveland G, Kwock L, Lawrence
T, Weissman RM, Nabell L, Fried FA, Staab EV, Risinger MA and Lin
S: Actin filament organization of the Dunning R3327 rat prostatic
adenocarcinoma system: Correlation with metastatic potential.
Cancer Res. 46:926–932. 1986.PubMed/NCBI
|
|
13
|
Xu W, Mezencev R, Kim B, Wang L, McDonald
J and Sulchek T: Cell stiffness is a biomarker of the metastatic
potential of ovarian cancer cells. PLoS One. 7:e466092012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bear JE and Haugh JM: Directed migration
of mesenchymal cells: Where signaling and the cytoskeleton meet.
Curr Opin Cell Biol. 30:74–82. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Verschueren H, Van der Taelen I, Dewit J,
De Braekeleer J and De Baetselier P: Metastatic competence of
BW5147 T-lymphoma cell lines is correlated with in vitro
invasiveness, motility and F-actin content. J Leukoc Biol.
55:552–556. 1994.PubMed/NCBI
|
|
16
|
Nürnberg A, Kitzing T and Grosse R:
Nucleating actin for invasion. Nat Rev Cancer. 11:177–187. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim TY, Vigil D, Der CJ and Juliano RL:
Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in
regulation of the cytoskeleton and cell motility. Cancer Metastasis
Rev. 28:77–83. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Carisey A, Tsang R, Greiner AM, Nijenhuis
N, Heath N, Nazgiewicz A, Kemkemer R, Derby B, Spatz J and
Ballestrem C: Vinculin regulates the recruitment and release of
core focal adhesion proteins in a force-dependent manner. Curr
Biol. 23:271–281. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Thakur RK, Yadav VK, Kumar A, Singh A, Pal
K, Hoeppner L, Saha D, Purohit G, Basundra R, Kar A, et al:
Non-metastatic 2 (NME2)-mediated suppression of lung cancer
metastasis involves transcriptional regulation of key cell adhesion
factor vinculin. Nucleic Acids Res. 42:11589–11600. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gilardi M, Bersini S, Calleja AB, Kamm RD,
Vanoni M and Moretti M: PO-12 - The key role of talin-1 in cancer
cell extravasation dissected through human vascularized 3D
microfluidic model. Thromb Res. 140 Suppl 1:S180–S181. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu M, Oberg K and Zhou Y: Expression and
function of vinculin in neuroendocrine tumors. Tumour Biol.
28:196–204. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang W, Mao YQ, Wang H, Yin WJ, Zhu SX
and Wang WC: MiR-124 suppresses cell motility and adhesion by
targeting talin 1 in prostate cancer cells. Cancer Cell Int.
15:492015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Samy MD, Tong WL, Yavorski JM, Sexton WJ
and Blanck G: T cell receptor gene recombinations in human tumor
specimen exome files: Detection of T cell receptor-β VDJ
recombinations associates with a favorable oncologic outcome for
bladder cancer. Cancer Immunol Immunother. 66:403–410. 2017.
View Article : Google Scholar : PubMed/NCBI
|
